Maternal Testosterone Levels are Associated with C-Peptide Levels in the Mexican American Subset of the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study Cohort

Abstract

Altered sex hormone levels are thought to play an important role in adult-onset diseases including obesity, cardiovascular disease, and diabetes. They contribute to these complex diseases through changes in their availability, which is influenced, in part, by binding proteins. Insulin resistance, which is characteristic of these diseases, along with increased insulin secretion, is a physiologic change that occurs normally during pregnancy. To determine the relationship between insulin resistance and sex hormone levels, we examined the associations of sex hormone-binding globulin (SHBG) and testosterone with measures of glycemia and insulinemia in a healthy pregnant population. We measured fasting serum SHBG and testosterone levels in 215 Hispanic mothers of Mexican ancestry from the HAPO Study cohort and tested for associations between SHBG and testosterone levels and maternal plasma glucose and C-peptide. After adjusting for confounding variables, serum total testosterone (TT) was positively associated with fasting C-peptide (0.18 μg/l higher for TT higher by 1 SD, p=0.001) and 1-h C-peptide (0.79 μg/l higher for TT higher by 1 SD, p<0.001). Free testosterone (FT) was also positively associated with fasting C-peptide (0.19 μg/l higher for FT higher by 1 SD, p<0.001), and 1-h C-peptide (0.83 μg/l higher for FT higher by 1 SD, p<0.001). Although these findings are from a single cohort, this study provides evidence for an association between testosterone and C-peptide during pregnancy in a nondiabetic Hispanic obstetric population.

• References

• 1 Ding EL, Song Y, Malik VS, Liu S. JAMA 2006; 295: 1288-1299
• 2 Williams GP. Eur J Cancer Prev 2010; 19: 256-271
• 3 Butte NF. Am J Clin Nutr 2000; 71: 1256S-1261S
• 4 Kuhl C. Diabetes 1991; 40: 18-24
• 5 Kerlan V, Nahoul K, Le Martelot MT, Bercovici JP. Clin Endocrinol (Oxf) 1994; 40: 263-267
• 6 Thadhani R, Wolf M, Hsu-Blatman K, Sandler L, Nathan D, Ecker JL. Am J Obstet Gynecol 2003; 189: 171-176
• 7 Uzelac PS, Li X, Lin J, Neese LD, Lin L, Nakajima ST, Bohler H, Lei Z. Placenta 2010; 31: 581-588
• 8 Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, Hadden DR, McCance DR, Hod M, McIntyre HD, Oats JJ, Persson B, Rogers MS, Sacks DA. N Engl J Med 2008; 358: 1991-2002
• 9 The HAPO Study Cooperative Research Group . The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. Int J Gynaecol Obstet 2002; 78: 69-77
• 10 Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, Damm P, Dyer AR, Leiva A, Hod M, Kitzmiler JL, Lowe LP, McIntyre HD, Oats JJ, Omori Y, Schmidt MI. Diabetes Care 2010; 33: 676-682
• 11 Javanbakht M, Singh AB, Mazer NA, Beall G, Sinha-Hikim I, Shen R, Bhasin S. J Clin Endocrinol Metab 2000; 85: 2395-2401
• 12 Choi HH, Gray PB, Storer TW, Calof OM, Woodhouse L, Singh AB, Padero C, Mac RP, Sinha-Hikim I, Shen R, Dzekov J, Dzekov C, Kushnir MM, Rockwood AL, Meikle AW, Lee ML, Hays RD, Bhasin S. J Clin Endocrinol Metab 2005; 90: 1531-1541
• 13 Singh AB, Lee ML, Sinha-Hikim I, Kushnir M, Meikle W, Rockwood A, Afework S, Bhasin S. J Clin Endocrinol Metab 2006; 91: 136-144
• 14 Mazer NA. Steroids 2009; 74: 512-519
• 15 Dokras A, Spaczynski RZ, Behrman HR, Duleba AJ. Fertil Steril 2003; 79: 492-497
• 16 Morisset AS, Dube MC, Drolet R, Pelletier M, Labrie F, Luu-The V, Tremblay Y, Robitaille J, John Weisnagel S, Tchernof A. J Matern Fetal Neonatal Med 2013; 26: 513-519
• 17 Zietz B, Cuk A, Hugl S, Buttner R, Straub RH, Bauer B, Daffner P, Scholmerich J, Palitzsch K. Eur J Intern Med 2000; 11: 322-328
• 18 Andersson B, Marin P, Lissner L, Vermeulen A, Bjorntorp P. Diabetes Care 1994; 17: 405-411
• 19 Hagenfeldt K, Janson PO, Holmdahl G, Falhammar H, Filipsson H, Frisen L, Thoren M, Nordenskjold A. Hum Reprod 2008; 23: 1607-1613
• 20 Bjercke S, Dale PO, Tanbo T, Storeng R, Ertzeid G, Abyholm T. Gynecol Obstet Invest 2002; 54: 94-98